PE20121396A1 - Composicion farmaceutica que comprende bromuro de glicopirronio y formoterol - Google Patents

Composicion farmaceutica que comprende bromuro de glicopirronio y formoterol

Info

Publication number
PE20121396A1
PE20121396A1 PE2012000865A PE2012000865A PE20121396A1 PE 20121396 A1 PE20121396 A1 PE 20121396A1 PE 2012000865 A PE2012000865 A PE 2012000865A PE 2012000865 A PE2012000865 A PE 2012000865A PE 20121396 A1 PE20121396 A1 PE 20121396A1
Authority
PE
Peru
Prior art keywords
formoterol
bromide
pharmaceutical composition
composition including
glycopyronium
Prior art date
Application number
PE2012000865A
Other languages
English (en)
Inventor
Sauro Bonelli
Francesca Usberti
Enrico Zambelli
Original Assignee
Chiesi Farma Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42107420&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20121396(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Chiesi Farma Spa filed Critical Chiesi Farma Spa
Publication of PE20121396A1 publication Critical patent/PE20121396A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/008—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/12—Aerosols; Foams
    • A61K9/124—Aerosols; Foams characterised by the propellant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M15/00—Inhalators
    • A61M15/009—Inhalators using medicine packages with incorporated spraying means, e.g. aerosol cans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B65—CONVEYING; PACKING; STORING; HANDLING THIN OR FILAMENTARY MATERIAL
    • B65B—MACHINES, APPARATUS OR DEVICES FOR, OR METHODS OF, PACKAGING ARTICLES OR MATERIALS; UNPACKING
    • B65B3/00—Packaging plastic material, semiliquids, liquids or mixed solids and liquids, in individual containers or receptacles, e.g. bags, sacks, boxes, cartons, cans, or jars
    • B65B3/04—Methods of, or means for, filling the material into the containers or receptacles
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B65—CONVEYING; PACKING; STORING; HANDLING THIN OR FILAMENTARY MATERIAL
    • B65B—MACHINES, APPARATUS OR DEVICES FOR, OR METHODS OF, PACKAGING ARTICLES OR MATERIALS; UNPACKING
    • B65B31/00—Packaging articles or materials under special atmospheric or gaseous conditions; Adding propellants to aerosol containers
    • B65B31/003—Adding propellants in fluid form to aerosol containers
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B65—CONVEYING; PACKING; STORING; HANDLING THIN OR FILAMENTARY MATERIAL
    • B65B—MACHINES, APPARATUS OR DEVICES FOR, OR METHODS OF, PACKAGING ARTICLES OR MATERIALS; UNPACKING
    • B65B7/00—Closing containers or receptacles after filling
    • B65B7/16—Closing semi-rigid or rigid containers or receptacles not deformed by, or not taking-up shape of, contents, e.g. boxes or cartons
    • B65B7/28—Closing semi-rigid or rigid containers or receptacles not deformed by, or not taking-up shape of, contents, e.g. boxes or cartons by applying separate preformed closures, e.g. lids, covers
    • B65B7/2842—Securing closures on containers
    • B65B7/285—Securing closures on containers by deformation of the closure

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Mechanical Engineering (AREA)
  • Dispersion Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Otolaryngology (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Anesthesiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • External Artificial Organs (AREA)

Abstract

REFERIDA A UNA COMPOSICION FARMACEUTICA QUE COMPRENDE BROMURO DE GLICOPIRRONIO Y FORMOTEROL O UNA SAL DEL MISMO, DISUELTOS EN UN PROPELENTE DE HIDROFLUOROALCANO (HFA) Y UN COSOLVENTE TAL COMO ETANOL, DONDE EL BROMURO DE GLICOPIRRONIO SE ENCUENTRA EN UNA CONCENTRACION DE ENTRE 0,005% Y 0,14% (P/P) Y EL FORMOTEROL EN UNA CONCENTRACION DE ENTRE 0,005% Y 0,07% (P/P). TAMBIEN COMPRENDE UNO O MAS INGREDIENTES FARMACEUTICAMENTE ACTIVOS SELECCIONADOS DE AGONISTAS BETA-2, CORTICOESTEROIDES TALES COMO EL DIPROPIONATO DE BECLOMETASONA, AGENTES ANTIMUSCARINICOS E INHIBIDORES DE FOSFODIESTERASA (IV). DICHA COMPOSICION ES UTIL EN EL TRATAMIENTO DE TRASTORNOS RESPIRATORIOS, INCLUYENDO EPOC
PE2012000865A 2009-12-23 2010-12-22 Composicion farmaceutica que comprende bromuro de glicopirronio y formoterol PE20121396A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP09180671 2009-12-23

Publications (1)

Publication Number Publication Date
PE20121396A1 true PE20121396A1 (es) 2012-10-24

Family

ID=42107420

Family Applications (2)

Application Number Title Priority Date Filing Date
PE2016000787A PE20160853A1 (es) 2009-12-23 2010-12-22 Terapia combinada para enfermedad pulmonar obstructiva cronica (epoc)
PE2012000865A PE20121396A1 (es) 2009-12-23 2010-12-22 Composicion farmaceutica que comprende bromuro de glicopirronio y formoterol

Family Applications Before (1)

Application Number Title Priority Date Filing Date
PE2016000787A PE20160853A1 (es) 2009-12-23 2010-12-22 Terapia combinada para enfermedad pulmonar obstructiva cronica (epoc)

Country Status (40)

Country Link
US (3) US20110150782A1 (es)
EP (1) EP2515855B3 (es)
JP (2) JP5914354B2 (es)
KR (2) KR20170040392A (es)
CN (2) CN104055765B (es)
AR (2) AR079726A1 (es)
AU (3) AU2010334859A1 (es)
BR (1) BR112012015337B8 (es)
CA (1) CA2785321C (es)
CL (1) CL2012001705A1 (es)
CO (1) CO6541628A2 (es)
CY (2) CY1115116T1 (es)
DK (1) DK2515855T6 (es)
EA (2) EA021917B1 (es)
ES (1) ES2468840T7 (es)
FI (2) FI2515855T6 (es)
GE (1) GEP20156311B (es)
HR (1) HRP20140582T4 (es)
HU (1) HUS1800001I1 (es)
IL (1) IL260932B (es)
LT (1) LTC2515855I2 (es)
LU (1) LUC00060I2 (es)
MA (1) MA33823B1 (es)
MX (1) MX2012006878A (es)
MY (1) MY156949A (es)
NL (1) NL300923I2 (es)
NO (1) NO2018001I1 (es)
NZ (1) NZ600790A (es)
PE (2) PE20160853A1 (es)
PH (1) PH12012501066A1 (es)
PL (1) PL2515855T6 (es)
PT (1) PT2515855E (es)
RS (1) RS53391B2 (es)
SG (1) SG181868A1 (es)
SI (1) SI2515855T1 (es)
TN (1) TN2012000269A1 (es)
TW (1) TWI495468B (es)
UA (1) UA113832C2 (es)
WO (1) WO2011076843A2 (es)
ZA (1) ZA201204615B (es)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112012015334A2 (pt) * 2009-12-23 2016-03-15 Chiesi Farma Spa terapia combinada para doença pulmonar obstrutiva crônica
MX340264B (es) 2009-12-23 2016-07-04 Chiesi Farm Spa Formulacion de aerosol para la enfermedad pulmonar obstructiva cronica.
PE20160853A1 (es) * 2009-12-23 2016-09-14 Chiesi Farm Spa Terapia combinada para enfermedad pulmonar obstructiva cronica (epoc)
CA2827045A1 (en) * 2011-02-17 2012-08-23 Cipla Limited Compositions of glycopyrrolate and a beta2-agonist
CA2850084C (en) 2011-10-11 2020-07-07 Chiesi Farmaceutici S.P.A. Crystalline microparticles of a beta-agonist coated with a fatty acid
MX2015003731A (es) * 2012-10-23 2015-06-15 Cipla Ltd Composicion farmaceutica.
SI3569222T1 (sl) 2013-07-11 2024-10-30 Chiesi Farmaceutici S.P.A. Formulacija suhega praška, obsegajoča antiholinergik, kortikosteroid in beta-adrenergik, za dajanje z inhalacijo
BR112016014583B1 (pt) * 2013-12-30 2022-12-20 Chiesi Farmaceutici S.P.A Composição de solução farmacêutica em aerossol, inalador pressurizado de dose calibrada e uso da dita composição
HRP20180944T1 (hr) * 2013-12-30 2018-08-10 Chiesi Farmaceutici S.P.A. Stabilan pripravak stlačene aerosolne otopine kombinacije glikopironijeva bromida i formoterola
US9622483B2 (en) 2014-02-19 2017-04-18 Corning Incorporated Antimicrobial glass compositions, glasses and polymeric articles incorporating the same
US11039620B2 (en) 2014-02-19 2021-06-22 Corning Incorporated Antimicrobial glass compositions, glasses and polymeric articles incorporating the same
US11039621B2 (en) 2014-02-19 2021-06-22 Corning Incorporated Antimicrobial glass compositions, glasses and polymeric articles incorporating the same
US9554992B2 (en) 2014-06-09 2017-01-31 Chiesi Farmaceutici S.P.A. Inhalation particles comprising a combination of an anticholinergic, a corticosteroid and a beta-adrenergic
GB201416909D0 (en) * 2014-09-25 2014-11-12 Prosonix Ltd Method of forming concentrated solution
US20160310410A1 (en) 2015-04-24 2016-10-27 Glenmark Specialty S.A. Pharmaceutical compositions comprising arformoterol and glycopyrronium
MA50487B1 (fr) 2015-11-16 2021-09-30 Chiesi Farm Spa Procédé de préparation d'une formulation de poudre sèche contenant un anticholinergique, un corticostéroïde et un bêta-adrénergique
GB2545025A (en) * 2015-12-04 2017-06-07 Mexichem Fluor Sa De Cv Pharmaceutical composition
WO2017167737A1 (en) 2016-03-31 2017-10-05 Chiesi Farmaceutici S.P.A. Aerosol inhalation device
US10098837B2 (en) * 2016-07-28 2018-10-16 Chiesi Farmaceutici S.P.A. Combination therapy for COPD
EP3515425B1 (en) * 2016-09-19 2021-06-09 Mexichem Fluor S.A. de C.V. Pharmaceutical composition comprising salmeterol
CN114515284A (zh) 2016-09-19 2022-05-20 墨西哥氟石股份公司 药物组合物
EP3515439B1 (en) * 2016-09-19 2021-12-15 Mexichem Fluor S.A. de C.V. Pharmaceutical composition comprising tiotropium bromide
KR20220155395A (ko) * 2017-05-11 2022-11-22 키에시 파르마슈티시 엣스. 피. 에이. 항콜린제, 코르티코스테로이드 및 베타-아드레날린성 약물을 포함하는 건조 분말 제제의 제조 방법
KR20220155609A (ko) * 2017-05-11 2022-11-23 키에시 파르마슈티시 엣스. 피. 에이. 항콜린제, 코르티코스테로이드 및 베타-아드레날린성 약물을 포함하는 건조 분말 제제의 제조 방법
AU2019282562A1 (en) * 2018-06-04 2021-01-21 Lupin Inc. Stable pharmaceutical compositions for pressurized metered dose inhalers
US12616654B2 (en) * 2019-12-02 2026-05-05 Chiesi Farmaceutici S.P.A. Stainless steel can for pressurised metered dose inhalers
AU2021314977B2 (en) 2020-07-31 2025-03-13 Chemo Research, S.L. Combination therapy for inhalation administration
EP4225267A1 (en) * 2020-10-09 2023-08-16 Chiesi Farmaceutici S.p.A. A pharmaceutical formulation for pressurised metered dose inhaler
WO2023227783A1 (en) 2022-05-27 2023-11-30 Chiesi Farmaceutici S.P.A. A pharmaceutical formulation for pressurised metered dose inhaler
US20250312274A1 (en) 2022-05-27 2025-10-09 Chiesi Farmaceutici S.P.A. A pharmaceutical formulation for pressurised metered dose inhaler
WO2023227781A1 (en) 2022-05-27 2023-11-30 Chiesi Farmaceutici S.P.A. A pharmaceutical formulation for pressurised metered dose inhaler

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2956062A (en) 1959-02-26 1960-10-11 Robins Co Inc A H Esters of amino alcohols
EP0673240B1 (en) 1992-12-09 1999-03-24 Boehringer Ingelheim Pharmaceuticals Inc. Stabilized medicinal aerosol solution formulations
ATE283033T1 (de) * 1998-07-24 2004-12-15 Jago Res Ag Medizinische aerosolformulierungen
EP1102579B1 (de) * 1998-08-04 2003-03-19 Jago Research Ag Medizinische aerosolformulierungen
US20060171899A1 (en) * 1998-12-10 2006-08-03 Akwete Adjei Water-stabilized aerosol formulation system and method of making
IT1317720B1 (it) 2000-01-07 2003-07-15 Chiesi Farma Spa Dispositivo per la somministrazione di aerosol dosati pressurizzati inpropellenti idrofluoroalcani.
GB0008660D0 (en) 2000-04-07 2000-05-31 Arakis Ltd The treatment of respiratory diseases
US20060257324A1 (en) * 2000-05-22 2006-11-16 Chiesi Farmaceutici S.P.A. Pharmaceutical solution formulations for pressurised metered dose inhalers
JP5392880B2 (ja) * 2000-05-22 2014-01-22 キエシ・フアルマチエウテイチ・ソチエタ・ペル・アチオニ 加圧式定量吸入器のための安定な製薬学的溶液製剤
ATE375142T1 (de) 2001-03-30 2007-10-15 Jagotec Ag Medizinische aerosolformulierungen
US6667344B2 (en) 2001-04-17 2003-12-23 Dey, L.P. Bronchodilating compositions and methods
EP1321159A1 (en) 2001-12-21 2003-06-25 CHIESI FARMACEUTICI S.p.A. Pressurized metered dose inhaler (pMDI) actuators with laser drilled orifices
IL163843A0 (en) 2002-03-01 2005-12-18 Chiesi Farma Spa Formoterol superfine formulation
EP1575588A1 (en) 2002-12-16 2005-09-21 Boehringer Ingelheim Pharma GmbH & Co.KG Tiotropium containing hfc solution formulations
AR041873A1 (es) * 2003-10-30 2005-06-01 Pablo Cassara Srl Lab Una formulacion farmaceutica en aerosol adecuada para la inhalacion oral o nasal que contienen glucocorticoides en solucion estable al almacenamiento; un metodo para estabilzar formulaciones y uso de un agente estabilizante
DK1718336T3 (da) * 2004-02-06 2008-10-20 Meda Pharma Gmbh & Co Kg Ny kombination af anticholinergikum og beta-mimetika til behandling af luftvejssygdomme
AU2005210085B2 (en) 2004-02-06 2010-06-24 Meda Pharma Gmbh & Co. Kg The combination of anticholinergics and glucocorticoids for the long-term treatment of asthma and COPD
GB0410399D0 (en) 2004-05-10 2004-06-16 Arakis Ltd The treatment of respiratory disease
GB0411056D0 (en) 2004-05-18 2004-06-23 Novartis Ag Organic compounds
EP1616567A1 (en) 2004-07-16 2006-01-18 Boehringer Ingelheim Pharma GmbH & Co.KG Medicaments for inhalation comprising PDE IV inhibitors and glycopyrrolate salts
GB0505545D0 (en) 2005-03-17 2005-04-27 Glaxo Group Ltd Inhalation devices
WO2006105401A2 (en) 2005-03-30 2006-10-05 Schering Corporation Medicaments and methods combining an anticholinergic, a corticosteroid, and a long acting beta agonist
GB0523653D0 (en) 2005-11-21 2005-12-28 Novartis Ag Organic compounds
MX2008001115A (es) 2005-08-01 2008-03-13 Astrazeneca Ab Valvula para inhalador.
GB0523655D0 (en) 2005-11-21 2005-12-28 Novartis Ag Organic compounds
GB0523654D0 (en) * 2005-11-21 2005-12-28 Novartis Ag Organic compounds
GB0523656D0 (en) 2005-11-21 2005-12-28 Novartis Ag Organic compounds
WO2007071313A2 (en) 2005-12-21 2007-06-28 Meda Pharma Gmbh & Co Kg Combination of anticholinergics, glucocorticoids, beta2-ag0nists, pde4 inhibitor and antileukotriene for the treatment of inflammatory diseases
GB0613161D0 (en) 2006-06-30 2006-08-09 Novartis Ag Organic Compounds
EP1894568A1 (en) 2006-08-31 2008-03-05 Novartis AG Pharmaceutical compositions for the treatment of inflammatory or obstructive airway diseases
EP2200550B1 (en) 2007-10-18 2018-04-18 Rose U, LLC Topical glycopyrrolate formulations
WO2010144628A2 (en) * 2009-06-09 2010-12-16 Elevation Pharmaceuticals, Inc. Treatment of chronic obstructive pulmonary disease with nebulized beta 2-agonist or combined nebulized beta 2-agonist and anticholinergic administration
PE20160853A1 (es) * 2009-12-23 2016-09-14 Chiesi Farm Spa Terapia combinada para enfermedad pulmonar obstructiva cronica (epoc)
KR20120106753A (ko) * 2009-12-23 2012-09-26 키에시 파르마슈티시 엣스. 피. 에이. Ｃｏｐｄ용 에어로졸 제제
BR112012015334A2 (pt) * 2009-12-23 2016-03-15 Chiesi Farma Spa terapia combinada para doença pulmonar obstrutiva crônica
MX340264B (es) * 2009-12-23 2016-07-04 Chiesi Farm Spa Formulacion de aerosol para la enfermedad pulmonar obstructiva cronica.
SI3569222T1 (sl) * 2013-07-11 2024-10-30 Chiesi Farmaceutici S.P.A. Formulacija suhega praška, obsegajoča antiholinergik, kortikosteroid in beta-adrenergik, za dajanje z inhalacijo
HRP20180944T1 (hr) * 2013-12-30 2018-08-10 Chiesi Farmaceutici S.P.A. Stabilan pripravak stlačene aerosolne otopine kombinacije glikopironijeva bromida i formoterola
BR112016014583B1 (pt) 2013-12-30 2022-12-20 Chiesi Farmaceutici S.P.A Composição de solução farmacêutica em aerossol, inalador pressurizado de dose calibrada e uso da dita composição
US9554992B2 (en) * 2014-06-09 2017-01-31 Chiesi Farmaceutici S.P.A. Inhalation particles comprising a combination of an anticholinergic, a corticosteroid and a beta-adrenergic
US10098837B2 (en) * 2016-07-28 2018-10-16 Chiesi Farmaceutici S.P.A. Combination therapy for COPD

Also Published As

Publication number Publication date
CA2785321C (en) 2018-08-21
PT2515855E (pt) 2014-06-11
NZ600790A (en) 2014-09-26
HK1174566A1 (en) 2013-06-14
US20190046433A1 (en) 2019-02-14
EP2515855A2 (en) 2012-10-31
US10159645B2 (en) 2018-12-25
JP2016145239A (ja) 2016-08-12
BR112012015337B8 (pt) 2021-05-25
AU2016234895A1 (en) 2016-10-13
BR112012015337B1 (pt) 2021-05-04
NO2018001I2 (no) 2018-01-10
ZA201204615B (en) 2013-09-25
AU2016234895B2 (en) 2018-02-01
TW201129359A (en) 2011-09-01
EP2515855B1 (en) 2014-04-02
HRP20140582T4 (hr) 2023-06-09
CN102665679B (zh) 2014-11-26
DK2515855T3 (da) 2014-06-30
JP6283388B2 (ja) 2018-02-21
IL260932B (en) 2021-04-29
CL2012001705A1 (es) 2012-09-28
WO2011076843A2 (en) 2011-06-30
FIC20170064I1 (fi) 2017-12-29
ES2468840T7 (es) 2023-11-29
CN104055765B (zh) 2016-11-23
US20150328144A1 (en) 2015-11-19
DK2515855T6 (da) 2023-06-06
WO2011076843A3 (en) 2011-12-01
ES2468840T3 (es) 2014-06-17
PE20160853A1 (es) 2016-09-14
KR101757951B1 (ko) 2017-07-13
LUC00060I2 (es) 2018-03-16
MX2012006878A (es) 2012-07-04
AU2010334859A1 (en) 2012-07-12
UA113832C2 (xx) 2017-03-27
RS53391B (sr) 2014-10-31
HUS1800001I1 (hu) 2018-02-28
GEP20156311B (en) 2015-07-10
US20110150782A1 (en) 2011-06-23
EA201290375A1 (ru) 2013-01-30
PH12012501066A1 (en) 2016-03-02
AR115897A2 (es) 2021-03-10
BR112012015337A2 (pt) 2016-03-15
CY2017047I1 (el) 2018-04-04
HK1197036A1 (en) 2015-01-02
MY156949A (en) 2016-04-15
EA021917B1 (ru) 2015-09-30
LTPA2018001I1 (lt) 2018-02-12
RS53391B2 (sr) 2023-09-29
JP5914354B2 (ja) 2016-05-11
CA2785321A1 (en) 2011-06-30
JP2013515696A (ja) 2013-05-09
CO6541628A2 (es) 2012-10-16
NL300923I1 (en) 2018-01-17
CN102665679A (zh) 2012-09-12
SG181868A1 (en) 2012-07-30
NO2018001I1 (no) 2018-01-10
CN104055765A (zh) 2014-09-24
EA027778B1 (ru) 2017-08-31
AR079726A1 (es) 2012-02-15
MA33823B1 (fr) 2012-12-03
US11389401B2 (en) 2022-07-19
EA201590179A1 (ru) 2015-09-30
CY1115116T1 (el) 2016-12-14
NL300923I2 (en) 2019-07-22
TWI495468B (zh) 2015-08-11
FI2515855T6 (fi) 2023-06-02
HRP20140582T1 (hr) 2014-08-01
KR20120103653A (ko) 2012-09-19
TN2012000269A1 (en) 2013-12-12
EP2515855B3 (en) 2023-05-03
KR20170040392A (ko) 2017-04-12
AU2018202998A1 (en) 2018-05-17
SI2515855T1 (sl) 2014-08-29
LUC00060I1 (es) 2018-01-18
AU2016234895C1 (en) 2026-02-19
LTC2515855I2 (lt) 2019-05-10
PL2515855T6 (pl) 2023-12-18
PL2515855T3 (pl) 2014-08-29
CY2017047I2 (el) 2018-04-04

Similar Documents

Publication Publication Date Title
NZ600790A (en) Combination therapy for copd
PE20160997A1 (es) Composicion combinada de bromuro de glicopirronio y formoterol en solucion estable presurizada para aerosol
JP2010132695A5 (es)
PE20091852A1 (es) Formulacion farmaceutica que comprende un anticuerpo de ox40l
EP4548972A3 (en) (2s)-n-[(1s)-1-cyano-2-phenylethyl]-1,4-oxazepane-2-carboxamides as dipeptidyl peptidase i inhibitors
PE20091672A1 (es) Nueva dosificacion y formulacion
NZ708593A (en) Novel pyrazole derivative
PH12015501964B1 (en) Substituted 2-aza-bicyclo[2.2.1]heptane-3-carboxylic acid (benzyl-cyano-methyl)-amides inhibitors of cathepsin c
PE20160155A1 (es) Composiciones, metodos y sistemas para el suministro por via respiratoria de tres o mas agentes activos
CO6630082A2 (es) Tratamiento de lupus nefritis usando laquinimod
PE20070951A1 (es) Formulacion farmaceutica para aerosoles con dos o mas principios activos y al menos una sustancia tensioactiva
PE20240808A1 (es) Composiciones, metodos y sistemas para la administracion de farmacos en aerosol
PE20121467A1 (es) Formulacion de aerosol para la enfermedad pulmonar obstructiva cronica
PE20081789A1 (es) Composicion farmaceutica que contiene aclidino
UA98839C2 (en) N,n-disubstituted aminoalkylbiphenyl antagonists of prostaglandin d2 receptors
AR072805A1 (es) Composiciones intranasales formas galenicas y metodos de tratamiento.
RU2012125966A (ru) Комбинированное лечение хронического обструктивного заболевания легких
PE20071231A1 (es) Formulaciones farmaceuticas de pleconaril
BR112014004879A2 (pt) uso de inibidor de aromatase para tratamento de hipogonadismo e doenças relacionadas
MX2019001850A (es) Formulaciones para administracion oral de principios activos.
NZ714288A (en) Extended-release formulation for reducing the frequency of urination and method of use thereof
PE20170073A1 (es) Combinaciones de bromuro de tiotropio, formoterol y budesonida para el tratamiento de la copd
CO6220945A2 (es) Uso de una composicion que comprende formoterol y dipropianato de beclometasona para la prevencion y/o tratamiento de una exacerbacion de asma
CO7170176A2 (es) Nuevo compuesto que tiene la capacidad para inhibir la enzima deshidrogenasa11b-hidroxiesteroide tipo 1(11b-hsd1) o sal farmaceúticamente aceptable del mismo, método para producir el mismo, y composición farmaceútica que contiene el mismo como ingrediente activo
ECSP11011323A (es) Método o sistema que usa biomarcadores para el seguimiento de un tratamiento.

Legal Events

Date Code Title Description
FC Refusal
AE Restoration of lapsed or forfeited application
FC Refusal